Jump to main content
Topic: Medicare Part D
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
Read More
-
After 4 Years of Trump, Medicare and Medicaid Badly Need Attention
Read More
-
Modeling P-quad
Read More
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
Read More
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
Read More
-
List Price, Net Price, and the Rebate Caught in the Middle
Read More
-
Association of Rebates in Part D with Patient OOP and Federal Spending
Read More